Crossmark

Reprogramming tumor-associated macrophages using STING or TLR agonists: a promising strategy to enhance immunotherapy in hormone-dependent cancers

Crossref DOI link: https://doi.org/10.1136/jitc-2024-010950

Published Online: 2025-05-15

Published Print: 2025-05

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Sacristan Santos, Victor https://orcid.org/0000-0002-6517-7814
Pensado-López, Alba

García-Campelo, Rosario

Antolin Novoa, Silvia

Señaris Rodriguez, Rosa

Andón, Fernando Torres https://orcid.org/0000-0001-9235-1278
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III (CD23/00173)

Instituto de Salud Carlos III (CP22/00106)

Instituto de Salud Carlos III (PI24/00465)

Axencia Galega de Innovación (ED431B)

Axencia Galega de Innovación (IN607D-2023/09)

Worldwide Cancer Research (Worldwide Cancer Research (UK, 2024-2026))

MICIU (CAR-M anti-EGFR)
License Information

License valid from 2025-05-15